JP2008507282A5 - - Google Patents

Download PDF

Info

Publication number
JP2008507282A5
JP2008507282A5 JP2007522752A JP2007522752A JP2008507282A5 JP 2008507282 A5 JP2008507282 A5 JP 2008507282A5 JP 2007522752 A JP2007522752 A JP 2007522752A JP 2007522752 A JP2007522752 A JP 2007522752A JP 2008507282 A5 JP2008507282 A5 JP 2008507282A5
Authority
JP
Japan
Prior art keywords
therapeutic composition
autoantigen
expression vector
polypeptide
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007522752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507282A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/025878 external-priority patent/WO2006012416A2/en
Publication of JP2008507282A publication Critical patent/JP2008507282A/ja
Publication of JP2008507282A5 publication Critical patent/JP2008507282A5/ja
Pending legal-status Critical Current

Links

JP2007522752A 2004-07-20 2005-07-20 自己免疫および自己抗原に関連する疾患の特異的阻害 Pending JP2008507282A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58970704P 2004-07-20 2004-07-20
US61452904P 2004-09-29 2004-09-29
PCT/US2005/025878 WO2006012416A2 (en) 2004-07-20 2005-07-20 Specific inhibition of autoimmunity and diseases associated with autoantigens

Publications (2)

Publication Number Publication Date
JP2008507282A JP2008507282A (ja) 2008-03-13
JP2008507282A5 true JP2008507282A5 (cg-RX-API-DMAC7.html) 2009-04-02

Family

ID=35786697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007522752A Pending JP2008507282A (ja) 2004-07-20 2005-07-20 自己免疫および自己抗原に関連する疾患の特異的阻害

Country Status (7)

Country Link
US (1) US20090053249A1 (cg-RX-API-DMAC7.html)
EP (1) EP1778296B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008507282A (cg-RX-API-DMAC7.html)
CN (1) CN101068574B (cg-RX-API-DMAC7.html)
CA (1) CA2574802A1 (cg-RX-API-DMAC7.html)
IL (1) IL180817A0 (cg-RX-API-DMAC7.html)
WO (1) WO2006012416A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1616016B1 (en) * 2003-03-19 2012-11-14 Isogenis, Inc. Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain
EP2020240A1 (en) * 2007-07-30 2009-02-04 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Methods and substances for the treatment of Alzheimer's
EP2342321B1 (en) * 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) * 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9848587B2 (en) * 2013-02-20 2017-12-26 Regeneron Pharmaceuticals, Inc. Humanized T cell co-receptor mice
KR102181336B1 (ko) 2013-06-13 2020-11-24 오르제네시스 엘티디. 세포 집단, 이의 전환분화 방법 및 이용 방법
US20160158352A1 (en) * 2013-07-10 2016-06-09 The United States of America, as represented by the Secretary, Department of Health & Human Servic Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
US11123404B2 (en) 2016-01-07 2021-09-21 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Methods for generating immunotolerant responses
WO2018207179A1 (en) 2017-05-08 2018-11-15 Orgenesis Ltd. Transdifferentiated cell populations and methods of use thereof
AU2018338786A1 (en) * 2017-09-29 2020-04-16 Nantcell, Inc. Antigenic proteins and methods therefor
US12583894B2 (en) * 2018-04-04 2026-03-24 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of Lewy body disorders
AU2019256536C1 (en) 2018-04-19 2026-01-15 Baylor College Of Medicine Reprogramming CD4 T cells into cytotoxic CD8 cells by forced expression of CD8αβ and Class 1 restricted T cell receptors
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078998A (en) * 1985-08-02 1992-01-07 Bevan Michael J Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
JPH04506061A (ja) * 1989-03-15 1992-10-22 タイコシンスキー,マーク エル. Cd8に基づく製剤
US5601828A (en) * 1989-03-15 1997-02-11 Tkb Associates Limited Partnership CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment
US5672346A (en) 1992-07-27 1997-09-30 Indiana University Foundation Human stem cell compositions and methods
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
ES2072223B1 (es) 1993-11-25 1996-03-16 Lipotec Sa Liposomas encapsulando doxorubicina.
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US6143292A (en) 1995-05-25 2000-11-07 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
IL115199A (en) * 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
GB9524973D0 (en) * 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US5939250A (en) 1995-12-07 1999-08-17 Diversa Corporation Production of enzymes having desired activities by mutagenesis
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
WO1997025446A1 (en) * 1996-01-05 1997-07-17 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
US6060054A (en) * 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
US5763239A (en) 1996-06-18 1998-06-09 Diversa Corporation Production and use of normalized DNA libraries
US6211342B1 (en) 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
BR9713498A (pt) * 1996-11-08 2000-02-29 Idec Pharma Corp Identificação de interações de ligação singulares entre alguns anticorpos e os antìgenos co-estimulatórios b7.1 e b7.2 humanos
US5873458A (en) 1997-09-12 1999-02-23 Kao; Kuo-Min Drawer type CD box structure
GB9722779D0 (en) * 1997-10-28 1997-12-24 Isis Innovation Human CD8 as an inhibitor of the cellular immune system
EP1025242A1 (en) * 1997-10-30 2000-08-09 Cornell Research Foundation, Inc. A method of inhibiting an immune response to a recombinant vector
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US5945325A (en) 1998-04-20 1999-08-31 California Institute Of Technology Thermally stable para-nitrobenzyl esterases
US20020127205A1 (en) * 1998-08-31 2002-09-12 Albert Edge Cells expressing immunoregulatory molecules and uses therefor
US6509150B1 (en) * 1999-03-05 2003-01-21 Universite De Nantes Compositions and methods for recombinant Adeno-Associated Virus production
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
JP2002541845A (ja) * 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
US6544506B2 (en) * 2000-01-05 2003-04-08 Yeda Research & Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US6762031B2 (en) 2000-06-16 2004-07-13 University Of Medicine And Dentistry Of New Jersey Targeting viral vectors to specific cells
US6534052B1 (en) 2000-09-05 2003-03-18 Yong-Fu Xiao Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7026121B1 (en) * 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
GB0114533D0 (en) 2001-06-14 2001-08-08 Avidex Ltd Substances
EP1616016B1 (en) * 2003-03-19 2012-11-14 Isogenis, Inc. Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain
US9701019B2 (en) 2011-09-15 2017-07-11 Convergent Information Technologies Gmbh System and method for the automatic generation of robot programs
ES2741897T3 (es) 2012-02-13 2020-02-12 Radius Eng Inc Cartucho reutilizable para moldeo por inyección

Similar Documents

Publication Publication Date Title
Burgess et al. Narcolepsy: neural mechanisms of sleepiness and cataplexy
Goverman Immune tolerance in multiple sclerosis
Schneeberger et al. Active immunization therapies for Parkinson's disease and multiple system atrophy
Farina et al. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action
Sospedra et al. Immunology of multiple sclerosis
Anderton et al. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin
Candia et al. On peptides and altered peptide ligands: from origin, mode of action and design to clinical application (immunotherapy)
Waksman Immune regulation in adjuvant disease and other arthritis models: relevance to pathogenesis of chronic arthritis
McCombe et al. Sex differences in Guillain Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis
Villoslada et al. Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates
Anderton Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities
Prat et al. The immunopathogenesis of multiple sclerosis.
JP2020510698A5 (cg-RX-API-DMAC7.html)
Vaitaitis et al. CD 40‐mediated signalling influences trafficking, T‐cell receptor expression, and T‐cell pathogenesis, in the NOD model of type 1 diabetes
Sospedra et al. Antigen-specific therapies in multiple sclerosis
JP2024116146A (ja) 多発性硬化症における免疫優性タンパク質および断片
Falk et al. Induction and suppression of an autoimmune disease by oligomerized T cell epitopes: enhanced in vivo potency of encephalitogenic peptides
Ben‐Nun et al. Anatomy of T cell autoimmunity to myelin oligodendrocyte glycoprotein (MOG): Prime role of MOG44F in selection and control of MOG‐reactive T cells in H‐2b mice
Campos et al. Interleukin‐4‐dependent innate collaboration between iNKT cells and B‐1 B cells controls adaptative contact sensitivity
Fridkis-Hareli Design of Peptide Immunotherapies for MHC Class‐II‐Associated Autoimmune Disorders
JP2016513963A5 (cg-RX-API-DMAC7.html)
Monneaux et al. Intramolecular T cell spreading in unprimed MRL/lpr mice: Importance of the U1‐70k protein sequence 131–151
Kaushansky et al. ‘Multi-epitope-targeted’immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides
Furuzawa-Carballeda et al. Polymerized‐type I collagen induces upregulation of Foxp3‐expressing CD4 regulatory T cells and downregulation of IL‐17‐producing CD4+ T cells (Th17) cells in collagen‐induced arthritis
Stüve et al. DNA-based vaccines: the future of multiple sclerosis therapy?